Marine Staurosporine Analogues: Activity and Target Identification in Triple-Negative Breast Cancer

被引:1
|
作者
Chen, Ru-Yi [1 ]
Ding, Li-Jian [2 ]
Liu, Yan-Jun [1 ]
Shi, Jin-Jin [1 ]
Yu, Jing [1 ]
Li, Chang-Yun [1 ]
Lu, Jian-Fei [1 ]
Yang, Guan-Jun [1 ]
Chen, Jiong [1 ]
机构
[1] Ningbo Univ, Sch Marine Sci, State Key Lab Managing Biot & Chem Threats Qual &, Ningbo 315211, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Sch Pharm, Ningbo 315211, Peoples R China
关键词
staurosporine analogue; apoptosis; triple-negative breast cancer; cancer stem cells; cell migration; STEM-CELLS; RHODIUM(III) COMPLEX; INDOLE ALKALOIDS; NATURAL-PRODUCTS; KINASE; PROMOTES; APOPTOSIS; SNAIL; PATHOGENESIS; INHIBITION;
D O I
10.3390/md22100459
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality and drug resistance and no targeted drug available at present. Compound 4, a staurosporine alkaloid derived from Streptomyces sp. NBU3142 in a marine sponge, exhibits potent anti-TNBC activity. This research investigated its impact on MDA-MB-231 cells and their drug-resistant variants. The findings highlighted that compound 4 inhibits breast cancer cell migration, induces apoptosis, arrests the cell cycle, and promotes cellular senescence in both regular and paclitaxel-resistant MDA-MB-231 cells. Additionally, this study identified mitogen-activated protein kinase kinase kinase 11 (MAP3K11) as a target of compound 4, implicating its role in breast tumorigenesis by affecting cell proliferation, migration, and cell cycle progression.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer
    Firger, Jessica
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (08):
  • [42] MYC as a therapeutic target for the treatment of triple-negative breast cancer.
    Foley, Sarah A.
    Casten, Alina
    Kavanagh, Emma
    Synnott, Naoise C.
    Crown, John
    Larsson, Lars-Gunnar
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Population and target considerations for triple-negative breast cancer clinical trials
    Hyslop, Terry
    Michael, Yvonne
    Avery, Tiffany
    Rui, Hallgeir
    BIOMARKERS IN MEDICINE, 2013, 7 (01) : 11 - 21
  • [44] EphA2: An emerging target in triple-negative breast cancer
    Eckhardt, Bedrich L.
    Torres, Angie M.
    Woodward, Wendy A.
    Krishnamurthy, Savitri
    Meric-Bernstam, Funda
    Ueno, Naoto T.
    CANCER RESEARCH, 2018, 78 (04)
  • [45] Activity of dasatinib with chemotherapy in triple-negative breast cancer cells
    Tryfonopoulos, D.
    O'Donovan, N.
    Corkery, B.
    Clynes, M.
    Crown, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] GRB7-a novel target in triple-negative breast cancer
    Giricz, Orsi
    Pero, Stephanie C.
    Krag, David N.
    Sparano, Joseph A.
    Kenny, Paraic A.
    CANCER RESEARCH, 2011, 71
  • [48] Theranostics for Triple-Negative Breast Cancer
    Choi, Hyeryeon
    Kim, Kwangsoon
    DIAGNOSTICS, 2023, 13 (02)
  • [49] Advanced Triple-Negative Breast Cancer
    Patel, Grisma
    Prince, Alison
    Harries, Mark
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [50] What is triple-negative breast cancer?
    Irvin, William J., Jr.
    Carey, Lisa A.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2799 - 2805